From: Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
RB1 gen deletion | Total | p value | ||
---|---|---|---|---|
Negative n (%) | Positive n (%) | |||
RAI stage | ||||
0, 1, 2 | 25 (54) | 21 (46) | 46 | p > 0.05 |
3, 4 | 9 (64) | 5 (36) | 14 | |
Total | 34 | 26 | 60 | |
Treatment | ||||
Positive | 15 (62) | 8 (35) | 23 | p > 0.05 |
Negative | 24 (58) | 17 (42) | 41 | |
Total | 39 | 25 | 64 | |
β2 microglobuline | ||||
< 3.5 mg/dl | 11 (61) | 7 (39) | 18 | p > 0.05 |
> 3.5 mg/dl | 9 (60) | 6 (40) | 15 | |
Total | 20 | 13 | 33 | |
13q deletion rate | ||||
< 80% | 33 (63) | 19 (37) | 52 | p > 0.05 |
> 80% | 8 (50) | 8 (50) | 16 | |
Total | 41 (60) | 27 (40) | 68 | |
< 70% | 23 (60,5) | 15 (39,5) | 38 | p > 0.05 |
> 70% | 8 (42) | 11 (58) | 19 | |
Total | 31 (54) | 26 (46) | 57 | |
< 60% | 19 (59) | 13 (41) | 32 | p > 0.05 |
> 60% | 12 (48) | 13 (52) | 25 | |
Total | 31 (54) | 26 (46) | 57 | |
Deletion type | ||||
Monoallel | 37 (59) | 26 (41) | 63 | p > 0.05 |
Biallel | 4 (80) | 1 (20) | 5 | |
Total | 41 | 27 | 68 |